CME / ABIM MOC / CE

Precision Medicine for Treatment of Rare Diseases in Cardiology

Authors: Martha Grogan, MD, MS; Vallerie McLaughlin, MD; Omar Abou Ezzeddine, MDCM, MS; Lisa Cooper Hudgins, MD; Martha Kingman, DNP, APRN, FNP-C; Ahmad Masri, MD, MS; Jose Nativi-Nicolau, MD, MS, FACC, FHFSA; Brett W. Sperry, MD
CME / ABIM MOC / CE Released: 12/28/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 12/28/2022, 11:59 PM EST

Target Audience and Goal Statement

This activity is intended for cardiologists, pulmonologists, primary care physicians (PCPs), endocrinologists, nurses, and radiologists who care for patients with rare diseases in cardiology.

The goal of this activity is to raise the suspicion of the diagnosis of rare disease in cardiology by educating the learners about the signs, symptoms, diagnosis, and individualized treatment strategies.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical signs and symptoms to raise suspicion of rare cardiac conditions
- Current and emerging treatment options for rare cardiac conditions
Have greater competence related to
- Diagnosis of rare cardiac conditions
- Use of individualized treatment strategies for patients with rare cardiac conditions to optimize outcomes

Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Co-Chairs

Martha Grogan, MD, MS

Assistant Professor of Medicine
Director
Cardiac Amyloid Clinic
Department of Cardiovascular Medicine
Mayo Clinic
Rochester, Minnesota

Disclosures

Disclosure: Martha Grogan, MD, MS, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Akcea; Alnylam; Eidos; Pfizer; Prothena

Vallerie McLaughlin, MD

Professor of Cardiovascular Medicine
Director, Pulmonary Hypertension Program
University of Michigan
Ann Arbor, Michigan

Disclosures

Disclosure: Vallerie McLaughlin, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Acceleron; Actelion; Aerovate; Altavant; Bayer; Caremark; Eicos; Gossamer Bio; Merck; United Therapeutics
Received grants for clinical research from: Acceleron; Actelion; Reata; Sunovion; United Therapeutics

Faculty

Omar Abou Ezzeddine, MDCM, MS

Assistant Professor of Medicine
Mayo Clinic College of Medicine and Science
Director
Cardiac Sarcoidosis Clinic, Division of Circulatory Failure, Department of Cardiovascular Medicine
Rochester, Minnesota

Disclosures

Disclosure: Omar Abou Ezzeddine, MDCM, MS, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Pfizer

Lisa Cooper Hudgins, MD

Director, Pediatric Comprehensive Lipid Control Center, The Rogosin Institute
Associate Professor of Pediatrics, Weill Cornell Medicine
Associate Professor of Pediatrics in Medicine, Weill Cornell Medicine
Associate Attending Physician, New York-Presbyterian Hospital
New York, New York

Disclosures

Disclosure: Lisa Cooper Hudgins, MD, has disclosed no relevant financial relationships.

Martha Kingman, DNP, APRN, FNP-C

Nurse Practitioner
Pulmonary Services, Heart and Lung Center
University of Texas Southwestern Medical Center
Dallas, Texas

Disclosures

Disclosure: Martha Kingman, DNP, APRN, FNP-C, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Acceleron; Bayer; Johnson & Johnson; United Therapeutics

Ahmad Masri, MD, MS

Assistant Professor of Medicine
Division of Cardiovascular Medicine
Oregon State School of Medicine
Portland, Oregon

Disclosures

Disclosure: Ahmad Masri, MD, MS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alnylam; Bristol Myers Squibb; Cytokinetics; Eidos; Ionis/Akcea; Pfizer
Received grants for clinical research from: Akcea; Pfizer; Ultromics

Jose Nativi-Nicolau, MD, MS, FACC, FHFSA

Associate Professor of Medicine
University of Utah Health
Heart Failure and Transplant Cardiology
Cardiology Director, Utah Amyloidosis Program
Cardiology Director, Cardiovascular Intensive Care Unit
Salt Lake City, Utah

Disclosures

Disclosure: Jose Nativi-Nicolau, MD, MS, FACC, FHFSA, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Akcea/Ionis; Alnylam; Pfizer
Received grants for clinical research from: Akcea/Ionis; Alnylam; Eidos; Pfizer

Brett W. Sperry, MD

Cardiologist
Saint Luke's Mid America Heart Institute
Kansas City, Missouri

Disclosures

Disclosure: Brett W. Sperry, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alnylam; Pfizer
Served as a speaker or a member of a speakers bureau for: Pfizer

Editors

Meghan Coulehan, MPH

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Meghan Coulehan, MPH, has disclosed no relevant financial relationships.

Cheryl Perkins, MD, RPh

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Cheryl Perkins, MD, RPh, has disclosed no relevant financial relationships.

CME Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC 

Disclosures

Disclosure: Amanda Jett, PharmD, BCACP, has disclosed no relevant financial relationships.

Nurse Planner

Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC 

Disclosures

Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has disclosed no relevant financial relationships.

All other faculty, planners and non-faculty contributors involved in the planning, development, editing, and review of the content have no relevant financial relationships with ineligible companies.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Owns stock, stock options, or bonds: Roche Diagnostics Inc

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Cardiology

CME / ABIM MOC / CE

Precision Medicine for Treatment of Rare Diseases in Cardiology

Authors: Martha Grogan, MD, MS; Vallerie McLaughlin, MD; Omar Abou Ezzeddine, MDCM, MS; Lisa Cooper Hudgins, MD; Martha Kingman, DNP, APRN, FNP-C; Ahmad Masri, MD, MS; Jose Nativi-Nicolau, MD, MS, FACC, FHFSA; Brett W. Sperry, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 12/28/2021

Valid for credit through: 12/28/2022, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

PAH Present and Future: Current Strategies and Emerging Approaches

Dr Martha Kingman discusses current and emerging approaches for PAH.
Martha Kingman, DNP, APRN, FNP-C

Hope for HCM: What We Know About Cardiac Myosin Inhibition

Dr Ahmad Masri discusses what we know about cardiac myosin inhibition.
Ahmad Masri, MD, MS

Challenges in Diagnosis and Approaches to Improve ATTR Cardiomyopathy Diagnosis

Dr Brett Sperry addresses the challenges in ATTR diagnosis and strategies to improve diagnosis.
Brett W. Sperry, MD

New and Emerging Treatment Options for ATTR

Dr Nativi-Nicolau shares new and emerging treatment options for ATTR.
Jose Nativi-Nicolau, MD, MS, FACC, FHFSA

Advances in HoFH: Present and Emerging Treatment Options

Dr Lisa Hudgins discusses advances in treatment options for HoFH.
Lisa Cooper Hudgins, MD

Sarcoidosis, the Great Masquerader: Challenges in Diagnosis and Treatment

Dr Omar Ezzeddine reviews challenges in diagnosis and treating sarcoidosis.
Omar Abou Ezzeddine, MDCM, MS

Assessment Survey

Before you begin, please take this brief survey.

Page 1 of 9

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Co-Chairs

Martha Grogan, MD, MS

Vallerie McLaughlin, MD

Faculty

Omar Abou Ezzeddine, MDCM, MS

Lisa Cooper Hudgins, MD

Martha Kingman, DNP, APRN, FNP-C

Ahmad Masri, MD, MS

Jose Nativi-Nicolau, MD, MS, FACC, FHFSA

Brett W. Sperry, MD

Editors

Meghan Coulehan, MPH

Cheryl Perkins, MD, RPh

CME Reviewer

Amanda Jett, PharmD, BCACP

Nurse Planner

Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Precision Medicine for Treatment of Rare Diseases in Cardiology

Target Audience and Goal Statement

Disclosures

Co-Chairs

Martha Grogan, MD, MS

Vallerie McLaughlin, MD

Faculty

Omar Abou Ezzeddine, MDCM, MS

Lisa Cooper Hudgins, MD

Martha Kingman, DNP, APRN, FNP-C

Ahmad Masri, MD, MS

Jose Nativi-Nicolau, MD, MS, FACC, FHFSA

Brett W. Sperry, MD

Editors

Meghan Coulehan, MPH

Cheryl Perkins, MD, RPh

CME Reviewer

Amanda Jett, PharmD, BCACP

Nurse Planner

Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Precision Medicine for Treatment of Rare Diseases in Cardiology

Contents of This CME Activity

PAH Present and Future: Current Strategies and Emerging Approaches

Hope for HCM: What We Know About Cardiac Myosin Inhibition

Challenges in Diagnosis and Approaches to Improve ATTR Cardiomyopathy Diagnosis

New and Emerging Treatment Options for ATTR

Advances in HoFH: Present and Emerging Treatment Options

Sarcoidosis, the Great Masquerader: Challenges in Diagnosis and Treatment

Assessment Survey

CME Reviewer

CME Reviewer